Fulgent Genetics Inc Stock News

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Borsje - IR Ming Hsieh - CEO Brandon Perthuis - Chief Commercial Officer Larry

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.12% and 6.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Fulgent an underrated stock or a value trap?

Is Fulgent an underrated stock or a value trap?

Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.

Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.

Fullgent Genetics (FLGT) closed at $56.44 in the latest trading session, marking a -1.28% move from the prior day.

An acquisition and raised guidance have reinforced the bull case for the stock.

An acquisition and raised guidance have reinforced the bull case for the stock.

Fulgent Genetics Inc (NASDAQ: HOTH) agreed to acquire Inform Diagnostics, an independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners, for $170 mi

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient ca

Fulgent Genetics reported a better-than-expected FQ4 card. But, it could get much more challenging from FY22.

These three beaten-up companies could make your retirement fruitful if you invest today.

Fullgent Genetics (FLGT) closed at $61.50 in the latest trading session, marking a +0.87% move from the prior day.